BioNTech Publications Clause Samples

BioNTech Publications. During the Term, BioNTech will submit to Pfizer for review and approval any proposed academic, scientific and medical publication or public presentation which contains Confidential Information of Pfizer or its Representatives. In addition, BioNTech will submit to Pfizer for review and approval any proposed publication or public presentation proposed by BioNTech or its Affiliates or any of their respective Representatives that relates to the activities conducted under this Agreement, including the Research Plan, or otherwise relating to the BioNTech Technology, the Research Program Technology, the Pfizer Technology or any Candidate or Product in the Field. In both instances, such review and approval will be conducted for the purposes of preserving the value of the BioNTech Technology, the Research Program Technology and the Pfizer Technology and the rights granted or to be granted to Pfizer hereunder and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder will be submitted to Pfizer no later than [***] days before submission for publication or presentation (the “Pfizer Review Period”). Pfizer will provide its comments with respect to such publications and presentations within [***] days of its receipt of such written copy. The Pfizer Review Period may be extended for an additional [***] days in the event Pfizer can, within ten days of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. BioNTech will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this Section 8.5.2, including International Committee of Medical Journal Editors standards regarding authorship and contributions.